Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
GSK PHARMA MYLAN |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
GSK PHARMA Mar-23 |
MYLAN Dec-18 |
GSK PHARMA/ MYLAN |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,684 | 3,975 | - | |
Low | Rs | 1,231 | 2,188 | - | |
Sales per share (Unadj.) | Rs | 191.9 | 1,829.1 | - | |
Earnings per share (Unadj.) | Rs | 35.9 | 49.7 | - | |
Cash flow per share (Unadj.) | Rs | 39.8 | 392.1 | - | |
Dividends per share (Unadj.) | Rs | 32.00 | 0 | - | |
Avg Dividend yield | % | 2.2 | 0 | - | |
Book value per share (Unadj.) | Rs | 102.9 | 1,978.8 | - | |
Shares outstanding (eoy) | m | 169.41 | 514.50 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 7.6 | 1.7 | 450.6% | |
Avg P/E ratio | x | 40.6 | 62.0 | 65.5% | |
P/CF ratio (eoy) | x | 36.7 | 7.9 | 466.5% | |
Price / Book Value ratio | x | 14.2 | 1.6 | 909.5% | |
Dividend payout | % | 89.2 | 0 | - | |
Avg Mkt Cap | Rs m | 246,858 | 1,585,442 | 15.6% | |
No. of employees | `000 | NA | 35.0 | 0.0% | |
Total wages/salary | Rs m | 5,950 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 26,887.8 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 730.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 32,517 | 941,074 | 3.5% | |
Other income | Rs m | 1,007 | 0 | - | |
Total revenues | Rs m | 33,524 | 941,074 | 3.6% | |
Gross profit | Rs m | 8,033 | 243,515 | 3.3% | |
Depreciation | Rs m | 658 | 176,206 | 0.4% | |
Interest | Rs m | 18 | 45,262 | 0.0% | |
Profit before tax | Rs m | 8,364 | 22,047 | 37.9% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,288 | -3,507 | -65.2% | |
Profit after tax | Rs m | 6,076 | 25,554 | 23.8% | |
Gross profit margin | % | 24.7 | 25.9 | 95.5% | |
Effective tax rate | % | 27.4 | -15.9 | -171.9% | |
Net profit margin | % | 18.7 | 2.7 | 688.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 24,943 | 525,495 | 4.7% | |
Current liabilities | Rs m | 13,264 | 383,144 | 3.5% | |
Net working cap to sales | % | 35.9 | 15.1 | 237.4% | |
Current ratio | x | 1.9 | 1.4 | 137.1% | |
Inventory Days | Days | 97 | 84 | 116.4% | |
Debtors Days | Days | 216 | 93 | 231.4% | |
Net fixed assets | Rs m | 6,988 | 182,553 | 3.8% | |
Share capital | Rs m | 1,694 | 501 | 338.1% | |
Net worth | Rs m | 17,430 | 1,018,070 | 1.7% | |
Long term debt | Rs m | 0 | 1,098,825 | 0.0% | |
Total assets | Rs m | 31,930 | 2,730,861 | 1.2% | |
Interest coverage | x | 462.6 | 1.5 | 31,107.1% | |
Debt to equity ratio | x | 0 | 1.1 | 0.0% | |
Sales to assets ratio | x | 1.0 | 0.3 | 295.5% | |
Return on assets | % | 19.1 | 2.6 | 736.0% | |
Return on equity | % | 34.9 | 2.5 | 1,388.9% | |
Return on capital | % | 48.1 | 3.2 | 1,512.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 4,842 | 195,555 | 2.5% | |
From Investments | Rs m | 8,079 | -101,081 | -8.0% | |
From Financial Activity | Rs m | -15,433 | -91,101 | 16.9% | |
Net Cashflow | Rs m | -2,512 | 1,620 | -155.1% |
Compare GSK PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare GSK PHARMA With: BROOKS LAB AARTI DRUGS S.S.ORGANICS ALEMBIC PHARMA EMMESSAR CHM
Asian share markets are mixed today after US shares extended their losing streak to the longest since January 2024.